Radhakrishnan Maha
SEC insider (Form 3/4/5 filer). CIK 0002013423. Director at Candel Therapeutics, Inc. (CADL) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Jun 23, 2026. Located in BOSTON, MA.
Companies Radhakrishnan Maha has filed insider reports for
- Candel Therapeutics, Inc. (CADL): Director
- Entrada Therapeutics, Inc. (TRDA): Director
Radhakrishnan Maha
CIK: 0002013423
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Jun 23, 2026CADL
Candel Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
32K shares- - Jun 10, 2026TRDA
Entrada Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
19K shares- - Jun 4, 2025CADL
Candel Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
28.5K shares- - Jun 1, 2025TRDA
Entrada Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
38K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Jun 23, 2026 |  CADL Candel Therapeutics, Inc. | Award Stock Option (Right to Buy) | 32,000 | - | - | Direct |
| Jun 10, 2026 |  TRDA Entrada Therapeutics, Inc. | Award Stock Option (Right to Buy) | 19,000 | - | - | Direct |
| Jun 4, 2025 | CADL Candel Therapeutics, Inc. | Award Stock Option (Right to Buy) | 28,480 | - | - | Direct |
| Jun 1, 2025 | TRDA Entrada Therapeutics, Inc. | Award Stock Option (Right to Buy) | 38,000 | - | - | Direct |
1-4 of 4 transactions